BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19155986)

  • 1. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection.
    Mulley WR; Hudson FJ; Tait BD; Skene AM; Dowling JP; Kerr PG; Kanellis J
    Transplantation; 2009 Jan; 87(2):286-9. PubMed ID: 19155986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
    Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
    Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation.
    Brown CM; Abraham KA; O'Kelly P; Conlon PJ; Walshe JJ
    Transplant Proc; 2009 Nov; 41(9):3690-2. PubMed ID: 19917368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of rituximab therapy for treatment of acute humoral rejection.
    Kaposztas Z; Podder H; Mauiyyedi S; Illoh O; Kerman R; Reyes M; Pollard V; Kahan BD
    Clin Transplant; 2009; 23(1):63-73. PubMed ID: 19200217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is a single low-fixed dose of rituximab sufficient for treating acute humoral rejection after kidney transplantation?
    Kamar N; Rostaing L
    Transplantation; 2009 Jul; 88(1):142; author reply 142-3. PubMed ID: 19584695
    [No Abstract]   [Full Text] [Related]  

  • 6. High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis.
    Tanriover B; Wright SE; Foster SV; Roush KS; Castillo-Lugo JA; Fa K; Levy FL; Mejia A
    Transplant Proc; 2008 Dec; 40(10):3393-6. PubMed ID: 19100397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.
    Fehr T; Rüsi B; Fischer A; Hopfer H; Wüthrich RP; Gaspert A
    Transplantation; 2009 Jun; 87(12):1837-41. PubMed ID: 19543061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab, IVIG, and plasma exchange without graft local infusion treatment: a new protocol in ABO incompatible living donor liver transplantation.
    Ikegami T; Taketomi A; Soejima Y; Yoshizumi T; Uchiyama H; Harada N; Iguchi T; Hashimoto N; Maehara Y
    Transplantation; 2009 Aug; 88(3):303-7. PubMed ID: 19667930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab.
    Alausa M; Almagro U; Siddiqi N; Zuiderweg R; Medipalli R; Hariharan S
    Clin Transplant; 2005 Feb; 19(1):137-40. PubMed ID: 15659147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and treatment of acute humoral kidney allograft rejection.
    Gomes AM; Pedroso S; Martins LS; Malheiro J; Viscayno JR; Santos J; Dias L; Henriques AC; Sarmento AM; Cabrita A
    Transplant Proc; 2009 Apr; 41(3):855-8. PubMed ID: 19376371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens.
    Tanabe K; Ishida H; Shimizu T; Omoto K; Shirakawa H; Tokumoto T
    Contrib Nephrol; 2009; 162():61-74. PubMed ID: 19001814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure of anti-CD20 monoclonal antibody therapy to prevent antibody-mediated rejection in three crossmatch-positive renal transplant recipients.
    Matignon M; Tagnaouti M; Audard V; Dahan K; Lang P; Grimbert P
    Transplant Proc; 2007 Oct; 39(8):2565-7. PubMed ID: 17954175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
    Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
    Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.
    Jordan SC; Tyan D; Stablein D; McIntosh M; Rose S; Vo A; Toyoda M; Davis C; Shapiro R; Adey D; Milliner D; Graff R; Steiner R; Ciancio G; Sahney S; Light J
    J Am Soc Nephrol; 2004 Dec; 15(12):3256-62. PubMed ID: 15579530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation.
    Ibernón M; Gil-Vernet S; Carrera M; Serón D; Moreso F; Bestard O; Cruzado JM; Grinyó JM
    Transplant Proc; 2005 Nov; 37(9):3743-5. PubMed ID: 16386524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C4d-positive renal transplants: single-center clinical outcomes.
    Ciszek M; Ptasińska AP; Durlik M; Paczek L
    Clin Transpl; 2006; ():405-12. PubMed ID: 18365397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experience.
    Slatinska J; Honsova E; Burgelova M; Slavcev A; Viklicky O
    Ther Apher Dial; 2009 Apr; 13(2):108-12. PubMed ID: 19379149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy.
    Thaunat O; Patey N; Gautreau C; Lechaton S; Fremeaux-Bacchi V; Dieu-Nosjean MC; Cassuto-Viguier E; Legendre C; Delahousse M; Lang P; Michel JB; Nicoletti A
    Transplantation; 2008 Jun; 85(11):1648-53. PubMed ID: 18551073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABO blood group-incompatible living donor kidney transplantation: a prospective, single-centre analysis including serial protocol biopsies.
    Oettl T; Halter J; Bachmann A; Guerke L; Infanti L; Oertli D; Mihatsch M; Gratwohl A; Steiger J; Dickenmann M
    Nephrol Dial Transplant; 2009 Jan; 24(1):298-303. PubMed ID: 18728155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early recurrence of nephrotic syndrome (immunoglobulin m nephropathy) after renal transplantation successfully treated with combinations of plasma exchanges, immunoglobulin, and rituximab.
    Westphal S; Hansson S; Mjörnstedt L; Mölne J; Swerkersson S; Friman S
    Transplant Proc; 2006 Oct; 38(8):2659-60. PubMed ID: 17098031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.